Pharmaust Limited (AU:NUZ) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Neurizon Therapeutics Limited has filed an Investigational New Drug application with the FDA for its lead candidate, NUZ-001, to commence a Phase 2/3 clinical trial targeting ALS. This marks a significant milestone in the company’s efforts to address neurodegenerative diseases and could provide new hope for ALS patients. The trial is set to begin in the first half of 2025, pending FDA approval.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.